Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Event Details

Filter
WorldWebinar

HIPAA, 42 CFR Part 2, and FERPA - Rules for Managing Student Health Information

HIPAA, 42 CFR Part 2

Add this event to your calendar: iCal   Google Calendar

Who should attend?

Compliance Director CEO CFO Privacy Officer Security Officer Information Systems Manager HIPAA Officer Chief Information Officer Health Information Manager Healthcare Counsel/Lawyer Office Manager

Details

Date: Tuesday January 8, 2019

Time: 10:00 AM PST | 01:00 PM EST

Overview:

This session focuses on the issues of managing health information when it may that of students and may involve substance abuse treatment information.

HIPAA and FERPA allow a number of disclosures without consent that SAMHSA prohibits without consent. 

First we will explain how HIPAA relates to information management and release and explain the processes required for various releases of information under the HIPAA and FERPA rules, including release according to individual access requests, and under consents and HIPAA authorizations. 

While FERPA overrides HIPAA, both HIPAA and FERPA take a back seat to the rules under 42 CFR Part 2. When substance abuse treatment information is involved, first you need to understand how to identify it. We will discuss how to make it distinguishable from "regular"health information, so that the appropriate extra protections can be provided. You may be able to use functions in your EHR to flag the information, or you may create a manual process for tracking the information, if it is rarely handled in your organization. 

And the substance abuse treatment information you collect may or may not be under SAMHSA depending on whether or not you have a department or even a response team that specializes in SAMHSA-related situations. You need to understand your status under the rules before you release information inappropriately. We will discuss what qualifies treatment that falls under SAMHSA. 

If your organization provides services that create information that is under the SAMHSA regulations, you will need to establish the consent and release of information processes that are required to be followed for information releases under 42 CFR Part 2. This involves getting the proper consents upon establishment of the relationship, as well as managing consents for releases that may be necessary after the initial establishment of the relationship. The session will include an explanation of the consent and release requirements that must be followed. 

When you release information under HIPAA, there are no special notices required to be placed on the records. But when you release information under SAMHSA, each document must have a notice that explains that re-disclosure is not permitted without a new consent. 

Complicating matters are updated rules going into effect that will allow a consent that permits a re-release to a defined team of providers caring for the individual, but then require meticulous documentation of to whom the information has been released under such a consent. The session will go over the rules on consents and re-release of information. 

This session will explore the complications and requirements of each of the rules controlling student health information, HIPAA, FERPA, and 42 CFR Part 2, and provide insights into how to apply the rules in an education setting. 

Why should you Attend: For much of healthcare, HIPAA sets the standards for how to manage uses and disclosures of patient information, known as Protected Health Information (PHI). But when it comes to information about students, even health information is controlled under the FERPA rules. 

For information related to the treatment of substance use disorders, regulations of the Substance Abuse and Mental Health Services Administration (SAMHSA) under 42 CFR Part 2 prevail. These rules apply to information collected under SAMHSA, which may be difficult to separate from "regular" PHI in your records, and there are special rules for disclosure and re-disclosure of substance abuse treatment information. 

Student health information may be subject to some or all of these rules, so it is essential to know where each rule applies and which rules supersede each other.

A number of factors must be considered when managing the privacy and security of student information. School records are rather decisively controlled by the FERPA regulations, but those regulations don't always apply, and when they don't, HIPAA steps in with the necessary privacy and security controls. While many of the concepts in the rules are similar, there are extensive detail differences 

Today we are in the midst of an epidemic of substance abuse, and particularly opioid abuse, and more and more providers are involved in providing treatment to students with substance abuse issues. When substance abuse is involved, the rules of SAMHSA under 42 CFR Part 2 come into play and override both HIPAA and 42 CFR Part 2. 

But who is covered under the rules, what's involved in meeting them, and how do they interact with HIPAA? HIPAA allows a number of disclosures, for treatment, payment, and healthcare operations purposes, without consent from the individual being treated. 

SAMHSA rules, on the other hand, require consent for every disclosure or re-disclosure, and if the proper consents aren't obtained, the provider can be in violation of the rules and subject to penalties. 

Areas Covered in the Session:

What FERPA controls and how to Determine where it Applies
How FERPA and HIPAA Interact
What HIPAA allows, what SAMHSA requires, and the Differences will be Explained
We will Examine how to Deternmine if the Services you Provide Place you under FERPA or 42 CFR Part 2
We will Explore the means for Making sure Substance Abuse Treatment Information Receives the Appropriate Protections
The consent and release Requirements under HIPAA, FERPA, and 42 CFR Part 2 will be Explained
Re-release of Information Released under 42 CFR Part 2 will be Discussed
Sharing of information with Family and Friends in an overdose Incident will be Explored
The latest Guidance from the US Department of Health and Human Services on HIPAA and FERPA, as well as Harmonization of SAMHSA and HIPAA will be Explained

Who Will Benefit:
Compliance Director
CEO
CFO
Privacy Officer
Security Officer
Information Systems Manager
HIPAA Officer
Chief Information Officer
Health Information Manager
Healthcare Counsel/Lawyer
Office Manager

Speaker Profile 
Jim Sheldon-Dean is the founder and director of compliance services at Lewis Creek Systems, LLC, a Vermont-based consulting firm founded in 1982, providing information privacy and security regulatory compliance services to a wide variety of health care entities. 

Sheldon-Dean serves on the HIMSS Information Systems Security Workgroup, has co-chaired the Workgroup for Electronic Data Interchange Privacy and Security Workgroup, and is a recipient of the WEDI 2011 Award of Merit. He is a frequent speaker regarding HIPAA and information privacy and security compliance issues at seminars and conferences, including speaking engagements at numerous regional and national healthcare association conferences and conventions and the annual NIST/OCR HIPAA Security Conference in Washington, D.C. 


Price - $139
Contact Info:
Netzealous LLC - MentorHealth
Phone No: 1-800-385-1607
Fax: 302-288-6884 
Email: mentorhealth84@gmail.com
Website: http://www.mentorhealth.com/
Webinar Sponsorship: https://www.mentorhealth.com/control/webinar-sponsorship/
Follow us on : https://www.facebook.com/MentorHealth1
Follow us on :  https://www.linkedin.com/company/mentorhealth/
Follow us on : https://twitter.com/MentorHealth1
 

Prices

Price $139.

Contact

Roger Steven
mentorhealth84@gmail.com

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.